Literature DB >> 20210240

Telomerase RNA expression and DNA ploidy as prognostic markers of prostate carcinomas.

Athanassios Bantis1, Efstratios Patsouris, Maria Gonidi, Nikolaos Kavantzas, Angelos Tsipis, Anna-Maria Athanassiadou, Eleni Aggelonidou, Pauline Athanassiadou.   

Abstract

AIMS AND
BACKGROUND: The objective of this study was to determine whether there was a correlation between telomerase RNA expression and DNA ploidy status with clinicopathological parameters and biochemical recurrence after radical prostatectomy. STUDY
DESIGN: Telomerase RNA expression and DNA ploidy were evaluated in imprint smear samples obtained from 112 prostates after radical prostatectomy. The results were correlated with pathological stage, Gleason score and serum PSA.
RESULTS: Positive telomerse RNA expression was detected in 67.8% of prostate carcinomas. The multiple linear regression model showed a statistically significance increase in telomerase RNA expression with increased Gleason score (P < 0.0001) and preoperative serum PSA values (P = 0.0125). DNA ploidy status also varied significantly with Gleason score (P < 0.0001) and preoperative serum PSA values (P = 0.0110). Five patients with diploid tumors and negative telomerase RNA expression developed a recurrence. However, recurrence was associated with DNA aneuploidy (P = 0.001) as well as with high telomerase RNA overexpression (P = 0.001).
CONCLUSIONS: We conclude that telomerase RNA expression and DNA ploidy could be additional markers in the field of prognosis of prostate carcinomas.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20210240     DOI: 10.1177/030089160909500618

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  4 in total

Review 1.  Revisiting tumour aneuploidy - the place of ploidy assessment in the molecular era.

Authors:  Håvard E Danielsen; Manohar Pradhan; Marco Novelli
Journal:  Nat Rev Clin Oncol       Date:  2015-11-24       Impact factor: 66.675

2.  MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer.

Authors:  Javier A Baena-Del Valle; Qizhi Zheng; David M Esopi; Michael Rubenstein; Gretchen K Hubbard; Maria C Moncaliano; Andrew Hruszkewycz; Ajay Vaghasia; Srinivasan Yegnasubramanian; Sarah J Wheelan; Alan K Meeker; Christopher M Heaphy; Mindy K Graham; Angelo M De Marzo
Journal:  J Pathol       Date:  2017-11-14       Impact factor: 7.996

3.  SATB1, genomic instability and Gleason grading constitute a novel risk score for prostate cancer.

Authors:  Christoph Dumke; Timo Gemoll; Martina Oberländer; Sandra Freitag-Wolf; Christoph Thorns; Axel Glaessgen; Rinse Klooster; Silvère M van der Maarel; Jerker Widengren; Christian Doehn; Gert Auer; Jens K Habermann
Journal:  Sci Rep       Date:  2021-12-27       Impact factor: 4.379

Review 4.  Telomeres and telomerase in head and neck squamous cell carcinoma: from pathogenesis to clinical implications.

Authors:  Paolo Boscolo-Rizzo; Maria Cristina Da Mosto; Enrica Rampazzo; Silvia Giunco; Annarosa Del Mistro; Anna Menegaldo; Lorena Baboci; Monica Mantovani; Giancarlo Tirelli; Anita De Rossi
Journal:  Cancer Metastasis Rev       Date:  2016-09       Impact factor: 9.264

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.